Recurrence of Clostridioides difficile infection and mortality in older inpatients
- PMID: 38448711
- DOI: 10.1007/s41999-024-00942-x
Recurrence of Clostridioides difficile infection and mortality in older inpatients
Abstract
Purpose: The prevalence of Clostridioides difficile infection in older and frail population is extremely high and adverse outcomes, including future recurrences and premature mortality, are common. Nonetheless, the clinical risk profile for Clostridioides difficile recurrence in older people is still controversial. We aimed to investigate: 1) the association between Clostridioides difficile recurrence and 6-month mortality; 2) the risk factors for Clostridioides difficile recurrence after hospital discharge.
Methods: This is a retrospective study on adults with a first episode of Clostridioides difficile infection admitted to all Internal Medicine and Geriatrics Units of the University Hospital of Ferrara (Italy) between January 2018 and December 2020. For each patient, sociodemographic, clinical and laboratory data were collected through hospital database system. The primary and secondary outcomes were mortality and recurrence within 6 months from the first infectious episode, respectively.
Results: The mean age of the 386 enrolled patients was 77.8 years; 61.7% were females. Twelve percent patients had Clostridioides difficile recurrence and 32.1% patients died during the 6-month follow-up. At Cox analysis, after adjustment for the potential confounders, participants with recurrence reported a twofold risk of death compared to those without recurrence (HR, 95% CI 2.45, 1.59-3.78). Compared to patients treated with metronidazole, those treated with vancomycin showed a lower risk of recurrence (log-rank p < 0.001).
Conclusion: Clostridioides difficile recurrence is associated with a higher risk of mortality and it may itself be a marker of frailty and vulnerability. Vancomycin treatment during the infectious episode was associated with lower recurrence rate, as compared to metronidazole.
Keywords: Clostridioides difficile infection; Aged; Mortality; Recurrence.
© 2024. The Author(s), under exclusive licence to European Geriatric Medicine Society.
Similar articles
-
Outcomes associated with recent guideline recommendations removing metronidazole for treatment of non-severe Clostridioides difficile infection: a retrospective, observational, nationwide cohort study.Int J Antimicrob Agents. 2021 Mar;57(3):106282. doi: 10.1016/j.ijantimicag.2021.106282. Epub 2021 Jan 17. Int J Antimicrob Agents. 2021. PMID: 33465458
-
Comparative effectiveness of vancomycin and metronidazole on event-free survival after initial infection in patients with Clostridioides difficile-a German multicentre cohort study.Clin Microbiol Infect. 2024 Nov;30(11):1433-1438. doi: 10.1016/j.cmi.2024.08.003. Epub 2024 Aug 8. Clin Microbiol Infect. 2024. PMID: 39127107
-
Does Addition of Intravenous Metronidazole to Oral Vancomycin Improve Outcomes in Clostridioides difficile Infection?Clin Infect Dis. 2020 Dec 3;71(9):2414-2420. doi: 10.1093/cid/ciz1115. Clin Infect Dis. 2020. PMID: 31714955
-
Ridinilazole: a novel, narrow-spectrum antimicrobial agent targeting Clostridium (Clostridioides) difficile.Lett Appl Microbiol. 2022 Sep;75(3):526-536. doi: 10.1111/lam.13664. Epub 2022 Feb 11. Lett Appl Microbiol. 2022. PMID: 35119124 Free PMC article. Review.
-
A meta-analysis of metronidazole and vancomycin for the treatment of Clostridium difficile infection, stratified by disease severity.Braz J Infect Dis. 2015 Jul-Aug;19(4):339-49. doi: 10.1016/j.bjid.2015.03.006. Epub 2015 May 19. Braz J Infect Dis. 2015. PMID: 26001980 Free PMC article. Review.
Cited by
-
Epidemiology and Outcomes of Recurrent C Difficile Infection Among Hematopoietic Cell Transplant Recipients: A Single-center, Retrospective 10-year Study.Open Forum Infect Dis. 2024 Oct 1;11(10):ofae570. doi: 10.1093/ofid/ofae570. eCollection 2024 Oct. Open Forum Infect Dis. 2024. PMID: 39450393 Free PMC article.
-
Tips and tricks for gut microbiota investigation using scanning electron microscopy (SEM): going from sample preparation to imaging and landscape analysis.Gut Microbes. 2025 Dec;17(1):2512016. doi: 10.1080/19490976.2025.2512016. Epub 2025 Jun 9. Gut Microbes. 2025. PMID: 40491126 Free PMC article.
References
-
- McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE et al (2018) Clinical practice guidelines for clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis 66:e1-48. https://doi.org/10.1093/cid/cix1085 - DOI - PubMed - PMC
-
- Khanna S, Pardi DS (2010) The growing incidence and severity of Clostridium difficile infection in inpatient and outpatient settings. Expert Rev Gastroenterol Hepatol 4:409–416. https://doi.org/10.1586/egh.10.48 - DOI - PubMed
-
- Guery B, Menichetti F, Anttila V-J, Adomakoh N, Aguado JM, Bisnauthsing K et al (2018) Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial. Lancet Infect Dis 18:296–307. https://doi.org/10.1016/S1473-3099(17)30751-X - DOI - PubMed
-
- Feuerstadt P, Nelson WW, Drozd EM, Dreyfus J, Dahdal DN, Wong AC et al (2022) Mortality, Health Care Use, and Costs of Clostridioides difficile Infections in Older Adults. J Am Med Dir Assoc 23:1721-1728.e19. https://doi.org/10.1016/j.jamda.2022.01.075 - DOI - PubMed
-
- Archbald-Pannone L, Sevilleja JE, Guerrant R (2010) Diarrhea, clostridium difficile, and intestinal inflammation in residents of a long-term care facility. J Am Med Dir Assoc 11:263–267. https://doi.org/10.1016/j.jamda.2009.09.006 - DOI - PubMed - PMC
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical